Operating profit before amortization: myriad.com (MYGN)

Public company logo of Myriad Genetics (MYGN)

Myriad Genetics, Inc. (MYGN) generates revenue from molecular screening of hereditary pathologies for oncology centers and patients. EBITDA reflects current business dynamics, where the 0.00 mark represents the latest data. Stable cash flow is supported by inelastic demand for diagnostics, while the express delivery of biomaterials to central laboratories ensures the continuity of all operational processes.

MYGN Myriad: Profit before payment of interest, taxes and amortization in the range 11/23/2025 - 11/12/2026

Summary analytical data breakdowns for Myriad Genetics (MYGN)

- market price and analyst price targets:
Stock Price Myriad|MYGN - Price Target Chart
- company stock exchange capitalization indicators:
Market Capitalization Myriad Genetics|MYGN - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Myriad Genetics|MYGN - Company Book Value|Market Value to Book Value Ratio myriad.com|MYGN - Cumulative Company Assets
- business debt structure and liquidity details:
Debt to Capital Myriad Genetics, Inc.|MYGN - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Myriad Genetics Inc|MYGN - Company Aggregate Debts|Debts to Net Assets Myriad Genetics|MYGN - Company Long-Term Debt|Short-Term Debt Volume Myriad Genetics|Quick Liquidity Indicator myriad.com
- business earnings and investment ratios data:
MYGN - Net Income|Expected Net Profit Myriad Genetics, Inc.|MYGN - Price to Earnings Ratio|Future Price to Earnings Multiple myriad.com|MYGN - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Myriad Genetics|MYGN - Operating profit EBITDA|Net earnings per share (EPS TTM) Myriad Genetics|MYGN - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months myriad.com|MYGN - Net earnings per share growth this year|Expected earnings per share trend next year Myriad Genetics, Inc.
Summary company analytics:MYGN Myriad
Manufactured product of Myriad Genetics Corp

Amidst price wars in the genetic testing sector and pressure from insurance limits, this chart becomes a critical control tool. It demonstrates the actual ability of Myriad Genetics, Inc. (MYGN) to generate cash flow from core operations. The financial result before interest, taxes, and depreciation excludes the impact of debt load and amortization. This trend captures the distinction between random spikes and sustainable growth, which is essential for investors to timely rebalance portfolios as margins shift.

Competitors of Myriad Genetics, Inc. (MYGN)

Operating profit EBITDA Caris Corp CAI|GH - Profit before payment of interest, taxes and amortization|VCYT (veracyte.com) - Operating profit before amortization|CELC: Operating profit EBITDA|GRAIL Inc (GRAL) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Castle Biosciences Corp|Profit before payment of interest, taxes and amortization BNR|Operating profit before deduction of amortization VNRX (VolitionRx Limited)|BDSX - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Precipio PRPO|Operating income before deduction of amortization Check-Cap Ltd (CHEK)|Mainz Biomed - Operating profit EBITDA|Operating income before deduction of amortization OncoCyte Inc OCX